Suspension of ulipristal acetate for uterine fibroids during ongoing EMA ’s review of liver injury risk: Unfortunate timing during the Covid-19 pandemic!
EMA decided that with ulipristal acetate (UPA) treatment for uterine fibroids, should be discontinued due to the associated risk of hepatic failure, We analyzed whether the risk of recurrent symptoms due to fibroids may lead to an increased risk of Covid -19 infection and death, that would exceed the former risk of hepatic failure and transplantation.
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - Category: OBGYN Authors: Serge Rozenberg, Perrine Revercez, Maxime Fastrez, Jean Vandromme, Dario Bucella Tags: Full length article Source Type: research
More News: Biology | COVID-19 | Liver | Liver Transplant | OBGYN | Pandemics | Transplants | Urology & Nephrology